Abstract
The aim of the present study was to assess the efficacy and safety of teneligliptin in combination with metformin in Korean patients with type 2 diabetes mellitus who were inadequately controlled with metformin monotherapy. Patients [glycated haemoglobin (HbA1c) 7.0-10.0%, on stable metformin≥1000mg/day] were randomized 2:1 to receive 20mg teneligliptin plus metformin (n=136) or placebo plus metformin (n=68). The primary endpoint was the change in HbA1c levels from baseline to week 16. The mean baseline HbA1c was 7.9% in the teneligliptin group and 7.8% in the placebo group. The differences between the teneligliptin and placebo groups regarding changes in HbA1c and fasting plasma glucose levels were -0.78 % and -1.24 mmol/l (22.42mg/dl), respectively, at week 16. The incidence of adverse events was similar between the groups. The addition of teneligliptin once daily to metformin was effective and generally well tolerated in Korean patients with type 2 diabetes.
Original language | English |
---|---|
Pages (from-to) | 309-312 |
Number of pages | 4 |
Journal | Diabetes, Obesity and Metabolism |
Volume | 17 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2015 Mar 1 |
Bibliographical note
Publisher Copyright:© 2014 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology